Publicacións nas que colabora con José Luis Callejas Rubio (18)

2024

  1. Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis

    Nefrologia

  2. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2023

  1. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 6, pp. 837-847

  2. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

2021

  1. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Biologic therapy in refractory non-multiple sclerosis optic neuritis isolated or associated to immune-mediated inflammatory diseases. A multicenter study

    Journal of Clinical Medicine, Vol. 9, Núm. 8, pp. 1-13

2019

  1. LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients

    Rheumatology International, Vol. 39, Núm. 11, pp. 1875-1882

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2012

  1. Influence of the IL6 gene in susceptibility to systemic sclerosis

    Journal of Rheumatology, Vol. 39, Núm. 12, pp. 2294-2302

2010

  1. Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis

    Arthritis Research and Therapy, Vol. 12, Núm. 2

  2. Lack of association between IFNGR1 gene polymorphisms and biopsy-proven giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 1 SUPPL. 57

  3. Lack of association between IRF5 gene polymorphisms and biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 37, Núm. 1, pp. 136-140

  4. Lack of association between hypoxia inducible factor-1 alpha gene polymorphisms and biopsy-proven giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 1 SUPPL. 57

  5. Lack of association between the rs6920220 (G/A) polymorphism of the 6q23 region and biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 37, Núm. 5, pp. 1020-1023

2009

  1. Association between Toll-like receptor 4 gene polymorphism and biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 36, Núm. 7, pp. 1501-1506